hsd-016
Small moleculeexperimental
Clinical trial activity
3 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Sep 1, 2008 (NCT00739232)
Timeline
2000s
- Jan 1, 2008
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
HSD11B1 inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
C[C@@H]1CN(c2ccc(F)cc2C(F)(F)F)CCN1S(=O)(=O)c1cccc([C@@](C)(O)C(F)(F)F)c1- Mol. weight
- 514.46 g/mol
- Lipinski Ro5
- 1 violation(s)
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL4297286 ↗
Also known as
- hsd-016
- hsd-016
- hsd-016
- hsd-016
- (r)-1,1,1-trifluoro-2-(3-((r)-4-(4-fluoro-2-(trifluoromethyl)phenyl)-2-methylpiperazin-1-ylsulfonyl)phenyl)propan-2-ol
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT00838461 | Phase 1 | Mar 1, 2009 | Pfizer, Wyeth |
| NCT00740649 | Phase 1 | Oct 1, 2008 | Pfizer, Wyeth |
| NCT00739232 | Phase 1 | Sep 1, 2008 | Pfizer, Wyeth |
Showing 3 of 3 trials
Page 1 / 1